Last reviewed · How we verify

Cady, Roger, M.D. — Portfolio Competitive Intelligence Brief

Cady, Roger, M.D. pipeline: 2 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Dextromethorphan and quinidine Dextromethorphan and quinidine marketed
naratriptan HCl naratriptan HCl marketed Triptan (5-HT1B/1D receptor agonist) 5-HT1B receptor, 5-HT1D receptor Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Damanhour Teaching Hospital · 1 shared drug class
  2. Merck Sharp & Dohme LLC · 1 shared drug class
  3. Organon and Co · 1 shared drug class
  4. Teva Pharmaceuticals USA · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cady, Roger, M.D.:

Cite this brief

Drug Landscape (2026). Cady, Roger, M.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cady-roger-m-d. Accessed 2026-06-10.

Related